Entries by

Press Release

Bolt Biotherapeutics Announces Issuance of U.S. Patent for the Boltbody™ ISAC Technology and its Lead Development Candidate, BDC-1001


Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors Presented at: 2020 San Antonio Breast Cancer Symposium

Past Event

Bolt invited to present: 2020 Jefferies Virtual Healthcare Conference June 3, 2020

Media Coverage

Bolt Biotherapeutics Initiates Immunotherapy Trial of Lead Drug Candidate in HER2-Expressing Solid Tumors Precision Oncology News